US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by MIRA Pharmaceuticals
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
July 10, 2026
From
MIRA Pharmaceuticals
Via
ACCESS Newswire
Tickers
MIRA
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
July 06, 2026
From
MIRA Pharmaceuticals
Via
ACCESS Newswire
Tickers
MIRA
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
June 25, 2026
From
MIRA Pharmaceuticals
Via
ACCESS Newswire
Tickers
MIRA
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
June 17, 2026
From
MIRA Pharmaceuticals
Via
ACCESS Newswire
Tickers
MIRA